Sofosbuvir–velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India

BACKGROUND AND AIMS: In clinical studies, sofosbuvir–velpatasvir has demonstrated high cure rates and favorable tolerability in patients chronically infected with chronic hepatitis C virus (HCV) of any genotype. We evaluated the effectiveness and safety of sofosbuvir–velpatasvir administered with mi...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Hepatol Int
Главные авторы: Sood, Ajit, Duseja, Ajay, Kabrawala, Mayank, Amrose, Pradeep, Goswami, Bhadadev, Chowdhury, Abhijit, Sarin, Shiv Kumar, Koshy, Abraham, Hyland, Robert H., Lu, Sophia, Camus, Gregory, Stamm, Luisa M., Brainard, Diana M., Subramanian, G. Mani, Prasad, Madhura, Bhatia, Shobna, Shah, Samir R., Kapoor, Dharmesh, Shalimar, Saraswat, Vivek
Формат: Artigo
Язык:Inglês
Опубликовано: Springer India 2019
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6418070/
https://ncbi.nlm.nih.gov/pubmed/30790229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12072-019-09927-6
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы